Zoetis Inc (ZTS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zoetis Inc stock (ZTS) is currently trading at $116.71. Zoetis Inc PE ratio is 19.26. Zoetis Inc PS ratio (Price-to-Sales) is 5.40. Analyst consensus price target for ZTS is $151.00. WallStSmart rates ZTS as Hold.
Zoetis Inc (ZTS) stock price prediction for 2030: Base case $125.93. Bull case $157.41. Bear case $94.44. See full ZTS 2030 price forecast and methodology on WallStSmart.
- ZTS PE ratio analysis and historical PE chart
- ZTS PS ratio (Price-to-Sales) history and trend
- ZTS intrinsic value — DCF, Graham Number, EPV models
- ZTS stock price prediction 2025 2026 2027 2028 2029 2030
- ZTS fair value vs current price
- ZTS insider transactions and insider buying
- Is ZTS undervalued or overvalued?
- Zoetis Inc financial analysis — revenue, earnings, cash flow
- ZTS Piotroski F-Score and Altman Z-Score
- ZTS analyst price target and Smart Rating
Zoetis Inc
📊 No data available
Try selecting a different time range
ZTS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Zoetis Inc (ZTS)
ZTS trades 29% above its Graham fair value of $99.69, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Zoetis Inc (ZTS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Zoetis Inc (ZTS) Key Strengths (5)
Every $100 of shareholder equity generates $66 in profit
Keeps $35 of every $100 in revenue after operating costs
Keeps $28 of every $100 in revenue as net profit
101.07% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Zoetis Inc (ZTS) Areas to Watch (5)
Very expensive at 14.7x book value
Revenue growing slowly at 3.00% annually
Premium valuation at 5.4x annual revenue
Modest earnings growth at 6.10%
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Zoetis Inc (ZTS) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 3.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with Return on Equity at 66.00%, Operating Margin at 34.70%, Profit Margin at 28.20%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.87), Price/Sales (5.40), Price/Book (14.66) suggest expensive pricing. Growth concerns include Revenue Growth at 3.00%, EPS Growth at 6.10%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 66.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 3.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZTS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZTS's Price-to-Sales ratio of 5.40x trades 29% below its historical average of 7.6x (30th percentile). The current valuation is 64% below its historical high of 14.93x set in Dec 2021, and 70% above its historical low of 3.18x in Mar 2014. Over the past 12 months, the PS ratio has compressed from ~7.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zoetis Inc (ZTS) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Zoetis Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 9.5B with 3% growth year-over-year. Profit margins are strong at 28.2%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 66.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 28.2% and operating margin of 34.7% demonstrate strong pricing power and operational efficiency.
Debt-to-equity ratio of 2.85 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Debt management: total debt of 9.5B is significantly higher than cash (2.3B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Zoetis Inc.
Bottom Line
Zoetis Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zoetis Inc(ZTS)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.